- Precise Validation of Technology for Crossing the Blood-Brain Barrier (BBB) and Targeting Cancer Cells Using the MACO Model
- Development of an Anticancer Drug-Loaded Targeted Exosome Platform: Opening New Horizons in the Treatment of Intractable Brain Tumors

Panacell Biotech Signs Joint Research Agreement with U.S. H Medical School for Targeted Glioblastoma Therapy View original image

PANACELL BIOTECH (CEO Choi Seungho), a biotechnology specialist company, announced that on September 15 it signed a joint research agreement with a research team from an American medical university for the development of an exosome-based targeted therapy for glioblastoma.


This global joint research initiative aims to accelerate the development and commercialization of new treatments for intractable brain diseases by combining PANACELL BIOTECH’s proprietary exosome platform technology with the extensive clinical know-how of leading medical institutions both in Korea and abroad.


The American research team participating in this project belongs to a university hospital renowned for its world-class medical staff and research infrastructure. Similarly, the Korean researchers are composed of doctors from leading medical institutions with extensive clinical experience and advanced research facilities, raising expectations for strong research synergy.


The core of this joint research lies in verifying the therapeutic efficacy of an exosome drug delivery platform, loaded with anticancer agents, that can cross the blood-brain barrier (BBB) and precisely target only cancer cells. The researchers plan to use the middle cerebral artery occlusion (MACO) model to rigorously simulate and prove the process by which intravenously administered targeted exosomes efficiently traverse the BBB, reach target tumor cells within the brain, and induce cell death.


Existing glioblastoma treatments have been severely limited by the strong blocking function of the BBB, resulting in very low drug delivery rates into brain tissue. High-dose administration has been associated with serious side effects, including damage to healthy brain cells, as well as a high rate of recurrence.


If this study succeeds, it is expected to overcome the limitations of current therapies by securing both BBB penetrability and targeting ability through a next-generation drug delivery platform, potentially creating a groundbreaking new drug that could change the paradigm of the global glioblastoma treatment market.


Glioblastoma is the most common and deadliest malignant brain tumor. Its rapid progression and high risk of recurrence, even after surgery, have made it known as the “graveyard of therapeutic agents,” with no effective treatment options historically available for this intractable disease.


Through this joint research, PANACELL BIOTECH plans to strengthen its research capabilities and expand collaborations with domestic and global researchers in the development of exosome-based therapeutics.



Choi Seungho, CEO of PANACELL BIOTECH, stated, “Our collaboration with top-tier international medical institutions and major domestic general hospitals demonstrates our technology’s competitiveness at a global level,” adding, “Based on the validation of the MACO model, we will provide precise proof of BBB permeability and targeting performance for anticancer-loaded targeted exosomes, and quickly produce tangible results targeting the global market.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing